Gapping up
In reaction to earnings/guidance:
- CLOV +18%, OPEN +17.9%, SONO +11.2%, HIMS +9.8%, FOSL +8.6%, DDS +8.1%, MSP +7.6%, PLTR +7.3%, APP +6%, RIDE +5.7%, UP +5.3%, GDRX +4.2%, OGN +4.1%, AZEK +2.8%, EYE +2.1%, BOX +2.1%, SHC +1.8%, RGLD +1.7%, AVXL +1.6%, NIO +1.5%, BMBL +1.3%, MDP +1%
Other news:
- XONE +38.9% (agreed to be acquired by Desktop Metal [DM])
- CTSO +16.2% (granted a second Breakthrough Device designation for its DrugSorb-ATR Antithrombotic Removal System by FDA)
- XERS +13.6% (announced FDA acceptance of IND application for XeriSol levothyroxine for hypothyroidism)
- TPTX +13.1% (received sixth regulatory designation for repotrectinib from the FDA)
- BLDR +4.5% (authorizes the buyback up to $1 bln of common shares)
- KNBE +3.2% (prices offering of 10,430,910 shares of its Class A common stock by certain selling stockholders at $20.75 per share)
- RGLD +1.7% (acquires 1.0% net smelter return royalty)
- CCCC +1.6% (received FDA orphan drug designation for CFT7455 for treatment of multiple myeloma)
- OCFT +1.4% (Chairman and CEO and certain other members of mgmt intend to purchase up to $10 mln worth of ADSs during a three-month period following today)
- RDN +1.2% (approves $200 mln increase to share repurchase authorization)
Analyst comments:
- MHO +2.3% (upgraded to Outperform from Neutral at Wedbush)
- CARG +1.8% (upgraded to Buy from Hold at Needham)
- LYFT +1.7% (upgraded to Buy from Neutral at Northcoast)
- HFC +1% (upgraded to Equal Weight from Underweight at Wells Fargo)
- CGC +0.8% (upgraded to Hold from Underperform at Jefferies)